Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
BEDFORD, Mass., Feb. 13, 2024 -- Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and...
Source: marketscreener.com